CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first ...

Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating ...

Century Therapeutics (NASDAQ: IPSC) revealed an internal portfolio prioritization and capital allocation strategy that is expected to extend the cash runway into 2026. The company will deprioritize ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value ...

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...

Boundless Bio has announced a strategic portfolio prioritization aimed at optimizing its oncology programs, particularly focusing on the combination therapy of BBI-355 and BBI-825, alongside a new ...